Message #2 From:
NewsBot Date: November 14, 2007 05:34:59 AM
Arena Pharmaceuticals to Present at the CIBC World Markets 18th Annual Healthcare Conference
SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that the company is scheduled to present at the
CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007 at
10:20 a.m. Eastern Time (7:20 a.m. Pacific Time) at the Waldorf=Astoria Hotel
in New York City. Jack Lief, Arena's President and Chief Executive Officer, is
scheduled to provide a corporate overview of the company and its clinical
development and discovery programs.
A live audio webcast of the presentation will be available under the
investor relations section of Arena's website at http://www.arenapharm.com.
Please connect to Arena's website several minutes prior to the start of the
webcast to ensure adequate time for any software download that may be
necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory and
metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being
investigated in a Phase 3 clinical trial program for the treatment of obesity.
Arena's broad pipeline of novel compounds targeting G protein-coupled
receptors, an important class of validated drug targets, includes compounds
being evaluated independently and with its partners, Merck & Co., Inc. and
Ortho-McNeil Pharmaceutical, Inc.
Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the
company. 'APD' is an abbreviation for Arena Pharmaceuticals Development.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, preclinical and internal
and partnered clinical programs, and ability to develop compounds and
commercialize drugs. For such statements, Arena claims the protection of the
Private Securities Litigation Reform Act of 1995. Actual events or results may
differ materially from Arena's expectations. Factors that could cause actual
results to differ materially from the forward-looking statements include, but
are not limited to, Arena's planned clinical trials may not proceed at the
time Arena expects or at all, the results of preclinical studies or clinical
trials may not be predictive of future results, Arena's ability to partner
lorcaserin, APD125, APD791 or other of its compounds or programs, the timing,
success and cost of Arena's research, out-licensing endeavors and clinical
trials, Arena's ability to obtain additional financing, Arena's ability to
obtain and defend its patents, and the timing and receipt of payments and
fees, if any, from Arena's collaborators. Additional factors that could cause
actual results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims any intent or
obligation to update these forward-looking statements, other than as may be
required under applicable law.
Contacts: Jack Lief Mary Claire Duch President and CEO WeissComm Partners Media Relations David Walsey 212.301.7228 Director, Corporate Communications
Arena Pharmaceuticals, Inc. 858.453.7200, ext. 1682
